Skip to main
  1. Stocks
  2. Pasithea Therapeutics Corp
  3. Forecast
KTTA

KTTA Stock Forecast & Price Target

KTTA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Pasithea Therapeutics is supported by early clinical evidence showing PAS-004 produced consistent cNF shrinkage across all 15 evaluable participants, with a median best reduction of 41% and 87% of patients achieving more than 20% reduction, while 18 PN participants also showed volumetric decreases. The profile is further strengthened by de-risking regulatory and safety signals, including FDA clearance to proceed with a randomized Phase 2 in about 200 adults, no treatment-related serious adverse events or discontinuations, and only 33% rash at the Phase 2 doses, all Grade 1. Its outlook is also bolstered by a large underserved NF1 market, a potential priority review voucher, and management’s conservative valuation that still assigns meaningful upside from PAS-004 while leaving additional solid-tumor opportunity unmodeled.

Bears say

Pasithea Therapeutics is a speculative biotechnology company whose outlook is weighed down by a high risk of failed or inconclusive clinical trials, especially given the lack of a validated regulatory endpoint for cNF. Its development pipeline remains exposed to funding shortfalls and the need for dilutive capital raises, which could weaken shareholder value before any meaningful clinical or regulatory progress is achieved. Competition from approved and emerging MEK inhibitor therapies further raises the bar for PAS-004 and the broader CNS and oncology pipeline, making successful differentiation and commercialization uncertain.

KTTA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pasithea Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.

KTTA Analyst Forecast & Price Prediction

Get the latest KTTA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in KTTA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pasithea Therapeutics Corp (KTTA) Forecast

Analysts have given KTTA a Strong Buy based on their latest research and market trends.

According to 1 analysts, KTTA has a Strong Buy consensus rating as of Nov 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pasithea Therapeutics Corp (KTTA)


KTTA Analyst Forecast & Price Prediction

Get the latest KTTA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in KTTA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover KTTA stock data and trends